Prelude Therapeutics Incorporated

NASDAQ:PRLD

Biotechnology

Healthcare
$3.30 -3.22%

-$0.14 today

Market cap
$191.00M
Beta
1.01
P/E (TTM)
-4.5
EPS (TTM)
-$0.94
52W Low $0.75High $5.54

Volume 0.23M

Average 0.38M

PRLD Total Debt

Short-term and long-term borrowings combined.

Prelude Therapeutics IncorporatedNASDAQ: PRLD

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt broadly unchanged from a year ago

Total debt stood at $17.72M at the end of Q1 FY2026, down 1.1% from a year earlier and down 0.4% from the prior quarter. Over 3 fiscal years it compounded at +113.3% a year.

Context

  • Total debt amounted to 14.8% of total assets at the end of Q1 FY2026, up 2.1 pp from a year earlier.
  • Total debt increased in 2 of the last 3 fiscal years.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -1.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$17.72M-0.4% QoQ
Last fiscal yearDec 2025
$17.79M-1.3% YoY
Year agoMar 2025
$17.92M-1.1% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.1%——
1 year-1.3%——
3-year CAGR+113.3%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
17.79M USD
Year-over-year change
-1.3%
4-year CAGR
+78.8%

Total Debt vs competitors

How PRLD compares with its peers on the latest reported figures

  • Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -1.1% is the 8th highest of 11, against a peer median of +14.9%.
  • Total debt amounts to 14.8% of total assets for PRLD, versus a peer median of 18.5%.
PRLD Competitors
Total Debt for PRLD and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMRXImmuneering CorporationMar 2026$3.73B USD+91265.7%-7.6%1.7%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$186.62M USD-13.7%+96.0%59.3%
IVAInventiva S.A.Dec 2025€59.4M EUR+9.3%+19.8%23.9%
FHTXFoghorn Therapeutics Inc.Mar 2026$41.99M USD+20.5%-7.1%18.9%
OBIOOrchestra BioMed Holdings, Inc.Mar 2026$33.64M USD+104.5%-47.8%33.4%
CRBUCaribou Biosciences, Inc.Mar 2026$26.95M USD+2.8%-0.6%18.1%
PYXSPyxis Oncology, Inc.Mar 2026$18.26M USD-8.0%-0.4%28.4%
PRLDPrelude Therapeutics IncorporatedMar 2026$17.72M USD-1.1%+113.3%14.8%
TNYATenaya Therapeutics, Inc.Mar 2026$10.12M USD-21.6%-10.5%7.5%
AVTXAvalo Therapeutics, Inc.Mar 2026$2.33M USD+190.6%-50.4%2.3%
EPRXEupraxia Pharmaceuticals Inc.Mar 2026$2.01M USD+3715.1%-76.7%1.4%
Peer median (excluding PRLD) —+14.9%-7.3%18.5%

Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents31.83M30.61M25.29M12.47M35.26M
Short-term Investments259.41M171.12M207.64M121.14M67.96M
Net Receivables00000
Inventory00000
Other Current Assets02.65M2.65M2.28M2.48M
Total Current Assets295.12M204.38M235.59M135.9M105.69M
Property, Plant & Equipment (Net)5.64M6.7M37.74M35.47M32.28M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets4.35M9.42M4.34M4.15M3.35M
Total Non-current Assets9.98M16.12M42.08M39.62M35.62M
Total Assets305.1M220.5M277.67M175.52M141.32M
Account Payables7.84M6.78M4.58M7.73M3.98M
Short-term Debt00000
Tax Payables00000
Deferred Revenue000033.73M
Other Current Liabilities5.01M6.21M6.61M9.79M5.4M
Total Current Liabilities19.2M21.7M21.83M25.64M52.99M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00001.8M
Other Non-current Liabilities03.36M3.34M3.09M2.84M
Total Non-current Liabilities03.36M18.75M18.42M19.68M
Total Liabilities19.2M25.06M40.58M44.06M72.68M
Common Stock5K5K5K5K5K
Retained Earnings(219.12M)(334.56M)(456.39M)(583.56M)(683.06M)
Accumulated OCI(711K)(1.69M)223K35K8K
Other Stockholders Equity00000
Minority Interest00000
Total Equity285.9M195.44M237.09M131.46M68.64M
Total Debt1.74M1.83M16.89M18.03M17.79M
Net Debt(30.09M)(28.77M)(8.4M)5.55M(17.47M)

Prelude Therapeutics Incorporated

NASDAQ:PRLD

Intrinsic Alpha fair value

Locked

Current Price

$3.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.